Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Saphris, Sycrest
Asenapine, an atypical antipsychotic, is used to treat schizophrenia and bipolar I disorder in adults. It primarily affects dopamine and serotonin receptors in the brain, helping to regulate mood and behavior. Asenapine belongs to the dibenzothiazepine class of chemical compounds.
For the treatment of schizophrenia and bipolar I disorder in adults.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Asenapine is not approved for the treatment of patients with dementia-related psychosis.
Outcome:
Increased sedation and dizziness
Mechanism:
Additive CNS depressant effects
Outcome:
Increased asenapine levels
Mechanism:
Inhibition of CYP1A2
Outcome:
Slightly decreased asenapine absorption
Mechanism:
Chelation
Most likely new formulation: Long-acting injectable (2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of asenapine maintaining its current FDA approval status for the next 5 years.
Atypical Antipsychotic
Dibenzothiazepine